Centogene N.V. (CNTG)
| Market Cap | 65.78M |
| Revenue (ttm) | 215.82M |
| Net Income (ttm) | -52.74M |
| Shares Out | 27.07M |
| EPS (ttm) | -2.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 592 |
| Open | 2.41 |
| Previous Close | 2.06 |
| Day's Range | 2.00 - 2.69 |
| 52-Week Range | 1.83 - 11.95 |
| Beta | -1.19 |
| Analysts | Buy |
| Price Target | 10.20 (+319.8%) |
| Earnings Date | Jun 29, 2022 |
About CNTG
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide ... [Read more...]
Financial Performance
In 2021, Centogene's revenue was 189.92 million, an increase of 47.94% compared to the previous year's 128.38 million. Losses were -46.41 million, 116.0% more than in 2020.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for CNTG stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 319.75% from the latest price.
News
CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare ...
Working together on the world's first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18 Working together on the world's first treatment th...
CENTOGENE's CentoCloud® Is Now CE-Marked as One of the Only Decentralized SaaS Platforms Compliant With European IVD ...
CE-marked clinical decision support platform enables laboratories to provide best-in-class diagnostics of genetic diseases CE-marked clinical decision support platform enables laboratories to provide be...
CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease D...
Newly established WGS recommendations published in the European Journal of Human Genetics
CENTOGENE to Present at the H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 19, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerati...
CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally
Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases
CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results
- Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments, Exceeds Guidance
CENTOGENE CEO Kim Stratton to Speak at BIO-Europe Spring® 2022 Conference
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 24, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, und...
CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, und...
CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer
ROSTOCK, Germany and BERLIN, March 17, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat ra...
CENTOGENE Announces Voting Results of Extraordinary General Meeting
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, unde...
CENTOGENE Announces CFO Transition and Appointment of Miguel Coego Rios as EVP Finance & Legal and Interim CFO
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, und...
Centogene Raises $62M Via Debt And Equity Financings To Support Growth Plan
Centogene N.V. (NASDAQ: CNTG) has closed a €15 million (approximately $17 million) private placement financing from investors led by DPE Deutsche Private Equity, TVM Capital Life Science, and Careventures.
CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, unde...
CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board
Nomination adds significant expertise to support pharma partnerships and an impressive track record in value creation Nomination adds significant expertise to support pharma partnerships and an impressi...
CENTOGENE Announces Nomination of Kim Stratton as Chief Executive Officer
Dr. Andrin Oswald resigns as CEO due to prolonged medical leave; Kim Stratton elected as successor Dr. Andrin Oswald resigns as CEO due to prolonged medical leave; Kim Stratton elected as successor
CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artifi...
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, und...
CENTOGENE's CentoCloud® Set to Revolutionize Rare Disease Diagnostics With Decentralized SaaS Platform for Laboratori...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, unde...
CENTOGENE Wins Award in Digital Healthcare Innovation for Artificial Intelligence (AI) Platform Leading Biomarker Dis...
Leveraging AI to Accelerate the Path From Diagnosis to Cure Leveraging AI to Accelerate the Path From Diagnosis to Cure
CENTOGENE Announces CEO to Take Temporary Medical Leave of Absence – Biopharmaceutical Industry Veteran Kim Stratton ...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, unde...
Why Centogene Shares Are Slumping After Q3 Earnings?
Centogene N.V. (NASDAQ: CNTG) reported Q3 sales of €30.2 million, down 17% Y/Y, driven by decreasing revenues from COVID-19 testing.
Centogene N.V. (CNTG) Reports Q3 Loss, Tops Revenue Estimates
Centogene N.V. (CNTG) delivered earnings and revenue surprises of -83.05% and 11.58%, respectively, for the quarter ended September 2021.
CENTOGENE Reports Third Quarter 2021 Financial Results
Second Consecutive Quarter of Core Business Growth, Phasing Out COVID-19 Testing and Restructuring Organization for Core Rare Disease Business Second Consecutive Quarter of Core Business Growth, Phasing...
Earnings Preview For Centogene
Centogene (NASDAQ:CNTG) is set to give its latest quarterly earnings report on Wednesday, 2021-11-24. Here's what investors need to know before the announcement.
CENTOGENE to Announce Third Quarter 2021 Financial Results on November 24, 2021
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, und...
CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases
Providing Global Clinical Trial Support for Thalassemia and Sickle Cell Disease Will Deepen Understanding of Disease Characterization in the Search for a Treatment Providing Global Clinical Trial Suppor...